Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis

Launched by HOSPICES CIVILS DE LYON · May 20, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help diagnose a rare type of eye cancer called primary intraocular lymphoma (LIOP) in patients who have uveitis, which is an inflammation of the eye. The researchers want to see if a simple blood test that analyzes special immune cells (called NK cells) can quickly identify whether someone has LIOP or just regular uveitis. This is important because getting a fast and accurate diagnosis can lead to better treatment and improve outcomes for patients.

To participate in the trial, you must be at least 18 years old and have uveitis or have been diagnosed with LIOP but not yet treated. You also need to give your consent to take part in the study. If you join, you can expect to provide a blood sample, which will be analyzed to help determine your condition. The goal is to make diagnosing this difficult-to-identify cancer easier and quicker, potentially saving valuable time in getting the right treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • GENERAL CRITERIA
• • Male or female over 18 years of age,
• • Free, informed, written consent signed by the patient and the investigator (at the latest on the day of inclusion) and before any examination required by the research,
• • Patient affiliated to the social security system or beneficiary of such a system,
• • Maximum volume of sampling (care + research) per 30-day period to be adapted according to the patient's weight (Order of April 12, 2018 establishing the list of research mentioned in 2° of Article L. 1121-1).
• • SPECIFIC CRITERIA
• • - Patient affected in one or both eyes: of uveitis with another diagnosis than ocular lymphoma and without cerebral lymphoma (Group 1), or primary ocular lymphoma without brain involvement and never treated (Group 2), or primary ocular lymphoma without brain involvement, treated and considered in remission (IL10 HA level \< 10) (Group 3), or primary ocular lymphoma without brain involvement, and considered in relapse (IL10 HA level \> 30) (Group 4), or cerebral lymphoma with or without ocular involvement and without uveitis (Group 5), or cataract (pre- and post-op), glaucoma, retinal detachment or epiretinal retinal detachment or epiretinal membrane, but no brain damage or uveitis (group 6).
• Exclusion Criteria:
• • -GENERAL CRITERIA
• • Patient participating in an ongoing clinical trial at the time of the inclusion visit,
• • Pregnant women, women in labor or nursing mothers,
• • Persons deprived of liberty by a judicial or administrative decision,
• • Persons under psychiatric care,
• • Persons admitted to a health or social institution for purposes other than research,
• • Persons of full age who are subject to a legal protection measure (guardianship, curatorship).
• • SPECIFIC CRITERIA
• • Patient for whom the diagnosis of ocular or cerebral lymphoma is uncertain,
• • Patient with another systemic cancer that is evolving or in remission \< 2 years.